ArticleBiotechnology for biofuels2019
Metabolic engineering
Article in Biotechnology for biofuels, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 19 citations in OpenAlex.
- Efficient whole-cell biotransformation for gastrodin production via glycosyltransferase engineering and process optimization.Synthetic and systems biotechnology · 2026Article
- Tailoring Regioselectivity-Controlled UDP-Glycosyltransferase for Bidirectional Glycosylation of Tyrosol via Free Energy-Driven Pocket Reshaping and Tunnel Engineering.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Artificial microbial consortia for bioproduction processes.Engineering in life sciences · 2023Review
- Diversification of phenolic glucosides by two UDP-glucosyltransferases featuring complementary regioselectivity.Microbial cell factories · 2022Article
- Natural drug sources for respiratory diseases from Fritillaria: chemical and biological analyses.Chinese medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIcariside D2 is a plant-derived natural glycoside with pharmacological activities of inhibiting angiotensin-converting enzyme and killing leukemia cancer cells. Production of icariside D2 by plant extraction and chemical synthesis is inefficient and environmentally unfriendly. Microbial cell factory offers an attractive route for economical production of icariside D2 from renewable and sustainable bioresources.
resultsWe metabolically constructed the biosynthetic pathway of icariside D2 in engineered
conclusionsWe for the first time reported the engineered
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.